We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Deep Sequencing of Circulating Tumor DNA Detects Cancers Early

By LabMedica International staff writers
Posted on 28 Aug 2017
A recently developed blood test utilizes targeted error correction sequencing (TEC-Seq) of circulating tumor DNA to detect early-stage cancers.

The detection and analysis of cell-free DNA in patients’ blood are becoming increasingly accepted for cancer diagnosis. More...
However, this approach has generally been applied for the monitoring of patients with existing tumors. It has not been useful for early diagnosis of cancer because of insufficient sensitivity to detect very small tumors that only shed minute quantities of DNA into the blood, as well as difficulties with identifying cancer-associated genetic changes without knowing what mutations are present in the primary tumor.

To address these limitations, investigators at Johns Hopkins University (Baltimore, MD, USA) developed the TEC-Seq approach, which allowed ultrasensitive direct evaluation of sequence changes in circulating cell-free DNA using massively parallel sequencing. The TEC-Seq deep sequencing method, which reads the DNA base code 30,000 times, was used to screen patients' blood samples for mutations within 58 genes widely linked to various cancers.

Analysis of plasma from 44 healthy individuals identified genomic changes related to clonal hematopoiesis in 16% of asymptomatic individuals but no alterations in driver genes related to solid cancers. Evaluation of 200 patients with colorectal, breast, lung, or ovarian cancer detected somatic mutations in the plasma of 71, 59, 59, and 68%, respectively, of patients with stage I or II disease. Genomic sequencing of tumors removed from 100 of the 200 patients revealed that 82 had mutations in their tumors that correlated with the genetic alterations found in the blood.

"The challenge was to develop a blood test that could predict the probable presence of cancer without knowing the genetic mutations present in a person's tumor," said senior author Dr. Victor Velculescu, professor of oncology at Johns Hopkins University. "This study shows that identifying cancer early using DNA changes in the blood is feasible and that our high accuracy sequencing method is a promising approach to achieve this goal."

The TEC-Seq study was published in the August 16, 2017, online edition of the journal Science Translational Medicine.

Related Links:
Johns Hopkins University


Gold Member
Hematology Analyzer
Medonic M32B
Gold Member
Immunochromatographic Assay
CRYPTO Cassette
Automated Chemiluminescence Immunoassay Analyzer
MS-i3080
Hemodynamic System Monitor
OptoMonitor
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: Research has linked platelet aggregation in midlife blood samples to early brain markers of Alzheimer’s (Photo courtesy of Shutterstock)

Platelet Activity Blood Test in Middle Age Could Identify Early Alzheimer’s Risk

Early detection of Alzheimer’s disease remains one of the biggest unmet needs in neurology, particularly because the biological changes underlying the disorder begin decades before memory symptoms appear.... Read more

Microbiology

view channel
Image: The SMART-ID Assay delivers broad pathogen detection without the need for culture (Photo courtesy of Scanogen)

Rapid Assay Identifies Bloodstream Infection Pathogens Directly from Patient Samples

Bloodstream infections in sepsis progress quickly and demand rapid, precise diagnosis. Current blood-culture methods often take one to five days to identify the pathogen, leaving clinicians to treat blindly... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.